PT - JOURNAL ARTICLE AU - Arantxa Valdivia AU - Ignacio Torres AU - Víctor Latorre AU - Clara Francés-Gómez AU - Josep Ferrer AU - Lorena Forqué AU - Rosa Costa AU - Carlos Solano de la Asunción AU - Dixie Huntley AU - Roberto Gozalbo-Rovira AU - Javier Buesa AU - Estela Giménez AU - Jesús Rodríguez-Díaz AU - Ron Geller AU - David Navarro TI - Suitability of Two Rapid Lateral Flow Immunochromatographic Assays for Predicting SARS-CoV-2 Neutralizing Activity of Sera AID - 10.1101/2020.09.23.20198713 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.23.20198713 4099 - http://medrxiv.org/content/early/2020/09/25/2020.09.23.20198713.short 4100 - http://medrxiv.org/content/early/2020/09/25/2020.09.23.20198713.full AB - Purpose Assessment of commercial SARS-CoV-2 immunoassays for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody (NtAb) titers.Patients and Methods Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP) reporter-based pseudotyped neutralization assay (vesicular stomatitis virus coated with SARS-CoV-2 spike protein) was used. Test line intensity was scored using a 4-level scale (0 to 3+).Results Overall sensitivity of LFIC assays was 91.1% for the Wondfo SARS-CoV-2 Antibody test, 72.2% for the INNOVITA 2019-nCoV IgG, 85.6% for the INNOVITA 2019-nCoV IgM and 92.2% for the NtAb assay. Sensitivity increased for all assays in sera collected beyond day 14 after symptoms onset (93.9%, 79.6%,93.9% and 93.9%, respectively). Reactivities equal to or more intense than the positive control line (≥2+) in the Wondfo assay had a negative predictive value of 100% and a positive predictive value of 96.4% for high NtAb50 titers (≥1/160).Conclusions Our findings support the use of LFIC assays evaluated herein, particularly the Wondfo test, for COVID-19 diagnosis. We also find evidence that these rapid immunoassays can be used to predict high SARS-CoV-2-S NtAb50 titers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Valencian Government grant IDIFEDER/2018/056 to JRD, Generalitat Valenciana grant Covid_19-SCI to RG-R, Spanish National Research Council grant CSIC-COV19-082 and Fondo Supera Covid-19 grant BlockAce to RG-RAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the Research Ethics Committee of Hospital Clinico Universitario INCLIVA (March, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.